Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​Update to medical policy on maintenance treatment of opioid or alcohol use disorder

November 1, 2022

​Effective January 1, 2023, Independence Blue Cross will update its medical policy on maintenance treatment of opioid or alcohol use disorder for its Commercial members.

The policy will be updated to include the Company's coverage position as follows:

  • The Company's coverage position will be updated to include methadone maintenance therapy as Medically Necessary with criteria.
  • The requirement Individual participates in a comprehensive treatment program, which includes counseling and psychosocial support will be removed under BUPRENORPHINE (PROBUPHINE®) IMPLANTS and BUPRENORPHINE (SUBLOCADETM) INJECTION.
  • The requirement Individual has shown compliance with scheduled and random urine drug screening will be removed under BUPRENORPHINE (SUBLOCADETM) INJECTION.
  • Updates to ICD-10 diagnosis codes.

For more information, please refer to the policy notification, which was published on November 1, 2022.

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.